Morning Seminar October 30, 2007

The 69th JSH and the 49th JSCH.

Morning Seminar October 25, 2007

Intensive Care Med. 2007 Feb;33(2):230-6.
Posterior reversible encephalopathy syndrome in intensive care medicine.
Servillo G, Bifulco F, De Robertis E, Piazza O, Striano P, Tortora F, Striano S, Tufano R.

Morning Seminar October 23, 2007

Mol Cancer. 2007 Aug 30;6:55.
Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake.
Carosio R, Zuccari G, Orienti I, Mangraviti S, Montaldo PG.

Morning Seminar October 18, 2007

Blood. 2007 Oct 15;110(8):3071-7.
One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME, Corey L, Boeckh M.

Morning Seminar October 16, 2007

J Clin Oncol. 2007 Sep 10;25(26):4127-36.
Place and provision of palliative care for children with progressive cancer: a study by the Paediatric Oncology Nurses' Forum/United Kingdom Children's Cancer Study Group Palliative Care Working Group.
Vickers J, Thompson A, Collins GS, Childs M, Hain R; Paediatric Oncology Nurses' Forum/United Kingdom Children's Cancer Study Group Palliative Care Working Group.

Morning Seminar October 4, 2007

J Clin Oncol. 2007 Sep 10;25(26):4127-36.
Chemoradiotherapy in malignant glioma: standard of care and future directions.
Stupp R, Hegi ME, Gilbert MR, Chakravarti A.

J Clin Oncol. 2005 Dec 20;23(36):9359-68.
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS.

J Neurooncol. 2007 May;83(1):53-60.
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA.

Neuro Oncol. 2007 Apr;9(2):145-60.
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, Hayes M, Murgo A, Weiner S, Boyett JM.

Morning Seminar October 3, 2007

Cancer. 2007 Oct 1;110(7):1542-50.
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH.